The Nomination Committee’s proposal, with reference to

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 14, 2014 at 8:45 AM

The Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced today the Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors. The 2013-2014 Nomination Committee comprises representatives of the three largest shareholders in the company at the end of the third quarter of 2013 who have accepted a seat on the Nomination Committee, together with the Chairman of the Board. The composition of the 2013 -2014 Nomination Committee was as follows: · Anders Algotsson, Chairman of the Nomination Committee, representing AFA Försäkring · Annelie Enquist, representing Skandia Fonder · Göran Pettersson, Chairman of the Board of Medivir AB · Bo Öberg, representing the class A shareholders The Nomination Committee has agreed to propose, with reference to the upcoming 2014 Annual General Meeting, that a new Board of Directors be appointed by means of the re-election of the Board’s existing Members, namely Björn C Andersson, Anna Malm Bernsten, Anders Hallberg and Birgitta Stymne Göransson, and the new election of three Members, namely Anders Ekblom, Niklas Prager and Bertil Samuelsson. Birgitta Stymne Göransson is proposed to be elected Chairman of the Board. Rolf A Classon, Ingemar Kihlström, Göran Pettersson and Bo Öberg have declined re-election. Anders Ekblom, born 1954, is a physician (specialising in anaesthesia and intensive care), dentist, Doctor of Medicine, and an Associate Professor in physiology at the Karolinska Institute. Anders has previously worked at AstraZeneca for 19 years in a number of positions, including Executive Vice President Global Medicines Development, and CEO of AstraZeneca AB in Sweden. He has extensive experience of pharmaceutical development work in numerous therapeutic areas, including inflammation, cardiovascular disease, oncology, the nervous system and infectious diseases. He is currently a Member of the Boards of the Karolinska University Hospital and SwedenBio, and is a senior advisor for Phase4 Partners, UK. Niklas Prager, born 1970, holds a Master of Business Administration degree from the Stockholm School of Economics and the University of Michigan. Niklas has many years’ experience of senior executive positions in trade and industry, both as CEO and as Board Member, and has extensive experience of company management, sales and marketing. He has worked in both Sweden and the USA for Merck & Co. Inc. and has been the CEO of Pfizer AB, Qbtech AB and Envirotainer AB. Niklas is currently the Chairman of the Board of Qbtech AB and a Member of the Board of eGain Group AB. He is also a former Chairman of the Boards of BioPhausia AB, Envirotainer AB and Michael Berglund Search Group AB. Bertil Samuelsson, born 1950, gained a Ph.D. in 1980 as a post-doctoral research fellow under Professor E.J. Corey at Harvard University in the USA, and was an Associate Professor and Visiting Professor at Stockholm University in 1985. Bertil held the position of Chief Scientific Officer, and subsequently of Chief Scientific Officer of Research & Development at Medivir between 1999 and 2010. He has served, from 2011 to the present day, as the Chief Scientific Advisor for Medivir and is fully familiar with the company’s operations and its projects. He was previously, from 1987, Head of Medicinal Chemistry at AstraZeneca, Mölndal. He has held seats on the Boards of ACTAR, NovaSaid and Toscana Life Sciences Foundation and the Swedish Pharmaceutical Society, and has acted as an advisor to AstraZeneca R&D Bangalore. He has published over 170 peer-reviewed articles, including a large number in the area of infectious diseases, and is listed as a co-inventor on approximately 40 patent applications, a large number of which have been granted. For further information, please contact: Anders Algotsson, AFA Försäkring +46(8) 696 40 67

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vanessa Hering's Empathetic Model Wins 2026 Herizon Award

Recognizing a Game-Changer in Financial Wellness Vanessa Hering's name isn't just getting thrown around for no reason, folks. She's the client success officer at Beyond Finance, a heavyweight in the financial wellness arena, and she's just snagged the 2026 Herizon Award. This ain't some run-of-the-mill accolade; it acknowledges the profound changes she's spearheaded in...

Sesame Software's Game-Changer: Smooth CRM Switch

Why Leaving Salesforce Isn't as Crazy as It Sounds Stepping away from Salesforce isn't your run-of-the-mill decision for businesses. It’s more like abandoning ship, anticipating lurking dangers: losing cherished data, facing burdensome API restrictions, and fretting over years of trapped history. It’s not as simple as flipping a switch, and that’s what keeps most...

IGT and MGM Springfield Unveil Jackpot Games in MA

Milestone Event in Massachusetts Gaming Scene When IGT and MGM Springfield team up to unveil the first wide-area progressive slots games in Massachusetts, it’s more than just a new game on the floor—it's a seismic shift in the region's gambling landscape. We've got twenty new shiny wheels turning over at the MGM Springfield, with jackpots starting at a hefty $1.125...

Doximity Faces Class Action: Investor Guidance Needed

Doximity Lands in Hot Water: The Stakes for Investors Alright, traders, there's a storm brewing around Doximity (NYSE:DOCS), and it's a doozy. A class action lawsuit has been slapped on this digital platform for medical pros, and the accusations are serious. If you rode the wave and snagged yourself some shares between August 8, 2024, and May 13, 2026, you're right in the...

Waters Acquires MOBILion: Ion Mobility Meets AI

MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...

Protalix to Reveal Q3 2026 Results Amid Rare Disease Push

Looking Ahead to Protalix's Q3 Revelation Nobody's pretending it's a cakewalk to stay ahead in the biopharma sector, especially when you're tangoing with the unpredictable world of rare disease therapeutics. But here we are, with Protalix BioTherapeutics scheduling their third-quarter financial results announcement for November 10, 2026. If you've been tracking them—or...

Mesirow Taps Shawn Beber as New CEO: Strategic Leap

Beber's Big Move: Mesirow Bets on Experience When a company's betting big on its next move, it goes for someone who's seen a storm or two. Enter Shawn Beber. Mesirow's new main guy. The firm isn't playing small potatoes with this hire. Fresh off a long gig at CIBC, Beber brings a hefty bag of tricks and a track record of navigating the high seas, none more impressive than...

Windward Expands Maritime Scope with Azimut.ai Deal

An Invincible Maritime Shield When it comes to maritime intelligence, Windward just pulled a fast one. In a market where staying ahead of the game is like playing three-dimensional chess, they've snatched up Azimut.ai. This ain't some small fry; it's a visual intelligence firm poised to shore up Windward's grip on the elusive maritime world. Charting New Waters with...

Hidden Fences: A Smarter Choice for Pet Owners?

The Case for Invisible Fences Man's best friend meets modern containment! Why are hidden fences gaining traction in households across Culpeper, VA, and beyond? Pet Containment Expert Lawrence Sowers spills some valuable insights into why so many are ditching traditional fences. Practical reasons abound, folks! Keeping the Yard Beautiful Who wants their landscaping ruined...

Samsung Biologics Hits 'Negligible' ESG Risk Milestone

Samsung Biologics Achieves a Low-Risk Triumph You gotta hand it to Samsung Biologics for hitting a 'Negligible Risk' rating. Their latest score? A cool 9.0. That’s like walking into the pharmaceuticals room and getting a standing ovation. It's no small feat—climbing up from a 'Low Risk' rating to the top tier in Morningstar Sustainalytics' playbook. For us spectating...